CN114846006B - 杂环化合物及其制备方法和用途 - Google Patents
杂环化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN114846006B CN114846006B CN202080086811.1A CN202080086811A CN114846006B CN 114846006 B CN114846006 B CN 114846006B CN 202080086811 A CN202080086811 A CN 202080086811A CN 114846006 B CN114846006 B CN 114846006B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- xrpd
- pattern
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410490957.2A CN118459459A (zh) | 2019-12-18 | 2020-12-17 | 杂环化合物及其制备方法和用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2019/126230 WO2021120045A1 (en) | 2019-12-18 | 2019-12-18 | Heterocyclic compounds, preparation methods and uses thereof |
| CNPCT/CN2019/126230 | 2019-12-18 | ||
| PCT/CN2020/137276 WO2021121330A1 (en) | 2019-12-18 | 2020-12-17 | Heterocyclic compounds, preparation methods and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410490957.2A Division CN118459459A (zh) | 2019-12-18 | 2020-12-17 | 杂环化合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114846006A CN114846006A (zh) | 2022-08-02 |
| CN114846006B true CN114846006B (zh) | 2024-04-26 |
Family
ID=76476909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080086811.1A Active CN114846006B (zh) | 2019-12-18 | 2020-12-17 | 杂环化合物及其制备方法和用途 |
| CN202410490957.2A Pending CN118459459A (zh) | 2019-12-18 | 2020-12-17 | 杂环化合物及其制备方法和用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410490957.2A Pending CN118459459A (zh) | 2019-12-18 | 2020-12-17 | 杂环化合物及其制备方法和用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11241437B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4077311A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7710449B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102965826B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN114846006B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2020410474A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3161852A1 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2021120045A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US12697337B2 (en) | 2021-03-11 | 2026-08-04 | InventisBio Co., Ltd. | Solid dispersions |
| PE20240088A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| WO2022246069A1 (en) | 2021-05-19 | 2022-11-24 | Teva Pharmaceuticals International Gmbh | Process for preparation of sotorasib and solid state form thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| AU2022421224A1 (en) | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN117462553A (zh) * | 2022-07-20 | 2024-01-30 | 益方生物科技(上海)股份有限公司 | 药物组合产品以及组合疗法 |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| CN121487951A (zh) | 2023-04-07 | 2026-02-06 | 锐新医药公司 | 大环ras抑制剂 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| EP4695261A1 (en) | 2023-04-14 | 2026-02-18 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120154618B (zh) * | 2025-05-15 | 2025-11-18 | 正大天晴药业集团股份有限公司 | 格索雷塞用于治疗肺癌的用途或其药物组合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201906821A (zh) * | 2017-05-22 | 2019-02-16 | 美商安進公司 | Kras g12c抑制劑及其使用方法 |
| TW201922739A (zh) * | 2017-09-08 | 2019-06-16 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020233592A1 (en) * | 2019-05-21 | 2020-11-26 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| CN108658972A (zh) | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种取代内酰胺类化合物及其制备方法和用途 |
| JP7369719B2 (ja) * | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN110256421A (zh) | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| CN111377918B (zh) | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
| CN111205286B (zh) | 2020-01-13 | 2022-12-13 | 中科苏州药物研究院 | 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用 |
-
2019
- 2019-12-18 WO PCT/CN2019/126230 patent/WO2021120045A1/en not_active Ceased
-
2020
- 2020-12-17 CN CN202080086811.1A patent/CN114846006B/zh active Active
- 2020-12-17 CA CA3161852A patent/CA3161852A1/en active Pending
- 2020-12-17 WO PCT/CN2020/137276 patent/WO2021121330A1/en not_active Ceased
- 2020-12-17 EP EP20901675.7A patent/EP4077311A4/en active Pending
- 2020-12-17 JP JP2022537316A patent/JP7710449B2/ja active Active
- 2020-12-17 AU AU2020410474A patent/AU2020410474A1/en active Pending
- 2020-12-17 KR KR1020227024223A patent/KR102965826B1/ko active Active
- 2020-12-17 CN CN202410490957.2A patent/CN118459459A/zh active Pending
-
2021
- 2021-02-10 US US17/172,984 patent/US11241437B2/en active Active
-
2022
- 2022-02-03 US US17/591,816 patent/US11865115B2/en active Active
-
2023
- 2023-11-22 US US18/517,156 patent/US12246020B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201906821A (zh) * | 2017-05-22 | 2019-02-16 | 美商安進公司 | Kras g12c抑制劑及其使用方法 |
| TW201922739A (zh) * | 2017-09-08 | 2019-06-16 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| WO2020233592A1 (en) * | 2019-05-21 | 2020-11-26 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| CN112585129A (zh) * | 2019-05-21 | 2021-03-30 | 益方生物科技(上海)股份有限公司 | 杂环化合物,其制备方法和用途 |
Non-Patent Citations (1)
| Title |
|---|
| Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors;Brian A. Lanman, et al.;J. Med. Chem.;第63卷(第1期);第52-65页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220226328A1 (en) | 2022-07-21 |
| US11241437B2 (en) | 2022-02-08 |
| AU2020410474A1 (en) | 2022-06-23 |
| US20210260067A1 (en) | 2021-08-26 |
| JP7710449B2 (ja) | 2025-07-18 |
| US12246020B2 (en) | 2025-03-11 |
| CN114846006A (zh) | 2022-08-02 |
| WO2021120045A1 (en) | 2021-06-24 |
| WO2021121330A1 (en) | 2021-06-24 |
| CA3161852A1 (en) | 2021-06-24 |
| US11865115B2 (en) | 2024-01-09 |
| EP4077311A1 (en) | 2022-10-26 |
| EP4077311A4 (en) | 2023-11-22 |
| JP2023506308A (ja) | 2023-02-15 |
| US20240156820A1 (en) | 2024-05-16 |
| KR102965826B1 (ko) | 2026-05-14 |
| CN118459459A (zh) | 2024-08-09 |
| KR20220118478A (ko) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102965826B1 (ko) | 헤테로고리 화합물, 이의 제조 방법 및 이의 용도 | |
| AU2017335242C1 (en) | Pyridine compound | |
| TW202110836A (zh) | 固態形式 | |
| KR101829595B1 (ko) | 3-(1-{3-[5-(1-메틸-피페리딘-4일메톡시)-피리미딘-2-일]-벤질}-6-옥소-1,6-디히드로-피리다진-3-일)-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법 | |
| JP2019518776A (ja) | Egfr阻害剤としてのアニリンピリミジン化合物の結晶 | |
| CA3059283A1 (en) | C5-anilinoquinazoline compounds and their use in treating cancer | |
| US10550101B2 (en) | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof | |
| JP2018502882A (ja) | 2−(5−(3−フルオロフェニル)−3−ヒドロキシピコリンアミド)酢酸の固体形態、その組成物及び使用 | |
| CN111989099A (zh) | 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途 | |
| US12116374B2 (en) | Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione | |
| TWI820182B (zh) | 四氫哌喃基胺基-吡咯并嘧啶酮化合物的固體形式 | |
| CN117729921A (zh) | 作为pd1/pd-l1抑制剂的化合物及其方法 | |
| HK40072166B (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| HK40072166A (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| TW202311267A (zh) | 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用 | |
| TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
| KR20190026910A (ko) | 4-시아노-n-(2-(4,4-다이메틸사이클로헥스-1-엔-1-일)-6-(2,2,6,6-테트라메틸테트라하이드로-2h-피란-4-일)피리딘-3-일)-1h-이미다졸-2-카르복스아미드의 결정질 형태 | |
| WO2025231053A1 (en) | Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide | |
| HK40109564A (en) | Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitor | |
| TW202519524A (zh) | 固態形式 | |
| WO2024255845A1 (zh) | 一类蛋白降解剂及其药物组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40072166 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20220802 Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Assignor: Yifang Biotechnology (Shanghai) Co.,Ltd. Contract record no.: X2023990000968 Denomination of invention: Heterocyclic compounds and their preparation methods and applications License type: Exclusive License Record date: 20231207 |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |